KIF13B and triple-A syndrome: Furthermore, BMT with WT bone marrows to Kif13b-/- mice or administration of senolytic therapy could largely reverse AAA progress in vivo, demonstrating that targeting macrophage KIF13B represents a novel therapeutic strategy for AAA.